Genfleet Therapeutics reported new phosphatidylinositol 3-kinase (PI3K) inhibitors with potential utility across oncology and additional therapeutic areas including Alzheimer’s disease, diabetes, Parkinson’s disease, asthma, and cardiovascular and allergic conditions. The disclosure highlights continued pipeline activity out of China-focused small-molecule R&D. The report did not provide clinical-stage data, focusing instead on the chemistry and potential target class coverage. For PI3K programs, preclinical differentiation often hinges on selectivity profiles, pathway biology context, and tolerability expectations. For partners and competitors, the disclosure is a signal that PI3K remains a live target category for medicinal chemistry efforts, with companies continuing to search for next-generation compounds that can outperform earlier-generation inhibitors or address resistance mechanisms.